2.44

1.21% -0.03

Esperion Therapeutics Inc (ESPR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ESPR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.47

Aprire:

$2.56

Volume 24 ore:

5.60M

Relative Volume:

1.13

Capitalizzazione di mercato:

$583.31M

Reddito:

$303.80M

Utile/perdita netta:

$-105.83M

Rapporto P/E:

-4.5539

EPS:

-0.5358

Flusso di cassa netto:

$-93.29M

1 W Prestazione:

-10.29%

1M Prestazione:

-28.86%

6M Prestazione:

-14.08%

1 anno Prestazione:

+62.67%

Intervallo 1D:

$2.385

$2.59

Intervallo di 1 settimana:

$2.385

$3.27

Portata 52W:

$0.6925

$4.175

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Nome

Esperion Therapeutics Inc

Settore

Healthcare (1116)

Industria

Drug Manufacturers - Specialty & Generic (83)

Telefono

734-887-3903

Indirizzo

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Dipendente

304

Cinguettio

@esperioninc

Prossima data di guadagno

2026-03-10

Ultimi documenti SEC

ESPR's Discussions on Twitter

Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ESPR Esperion Therapeutics Inc	2.44	583.31M	303.80M	-105.83M	-93.29M	-0.5358
TAK Takeda Pharmaceutical Co Adr	17.77	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.62	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.67B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.57	33.27B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.12	23.50B	3.18B	1.33B	1.04B	27.90

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-25	Iniziato	Piper Sandler	Overweight
2024-12-18	Iniziato	Goldman	Neutral
2024-12-17	Iniziato	Cantor Fitzgerald	Overweight
2024-06-20	Downgrade	BofA Securities	Neutral → Underperform
2024-01-03	Downgrade	BofA Securities	Buy → Neutral
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-01	Aggiornamento	Northland Capital	Under Perform → Market Perform
2023-06-15	Aggiornamento	BofA Securities	Underperform → Buy
2023-03-16	Downgrade	BofA Securities	Neutral → Underperform
2023-03-16	Downgrade	Northland Capital	Market Perform → Under Perform
2023-03-07	Aggiornamento	Credit Suisse	Underperform → Neutral
2023-02-27	Ripresa	BofA Securities	Neutral
2023-02-24	Aggiornamento	Jefferies	Hold → Buy
2023-02-03	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Downgrade	Credit Suisse	Neutral → Underperform
2022-05-05	Aggiornamento	JP Morgan	Underweight → Neutral
2022-03-10	Iniziato	H.C. Wainwright	Buy
2021-10-19	Downgrade	Credit Suisse	Outperform → Neutral
2021-10-14	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Downgrade	Stifel	Buy → Hold
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-11	Iniziato	Morgan Stanley	Equal-Weight
2021-02-12	Downgrade	Jefferies	Buy → Hold
2021-02-09	Downgrade	Goldman	Neutral → Sell
2021-01-15	Downgrade	BofA Securities	Buy → Neutral
2020-11-10	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-09-29	Ripresa	JP Morgan	Underweight
2020-08-11	Downgrade	Credit Suisse	Outperform → Neutral
2020-04-01	Ripresa	BofA/Merrill	Buy
2020-03-17	Aggiornamento	Citigroup	Neutral → Buy
2020-02-24	Downgrade	Northland Capital	Outperform → Market Perform
2020-02-14	Downgrade	Citigroup	Buy → Neutral
2019-09-16	Aggiornamento	Goldman	Sell → Neutral
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-06	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-04-26	Aggiornamento	Goldman	Sell → Neutral
2019-03-13	Aggiornamento	JP Morgan	Underweight → Neutral
2019-01-07	Reiterato	Needham	Strong Buy
2018-12-13	Iniziato	Goldman	Sell
2018-10-29	Aggiornamento	Northland Capital	Market Perform → Outperform
2018-10-16	Iniziato	BTIG Research	Buy
2018-08-17	Aggiornamento	Citigroup	Neutral → Buy
2018-07-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-05-03	Downgrade	JP Morgan	Neutral → Underweight
2018-05-02	Downgrade	BofA/Merrill	Buy → Underperform

Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

Mar 13, 2026

Esperion Therapeutics soars amid vague takeover speculation - MSN

Mar 13, 2026

Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN

Mar 13, 2026

FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

Mar 13, 2026

Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada

Mar 13, 2026

Mar 12, 2026

Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan

Mar 12, 2026

Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat

Mar 12, 2026

Mar 11, 2026

Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis

Mar 11, 2026

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - Yahoo Finance

Mar 11, 2026

Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com

Mar 11, 2026

What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat

Mar 11, 2026

Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm

Mar 11, 2026

Mar 10, 2026

Esperion Therapeutics Q4 2025 earnings preview - MSN

Mar 10, 2026

ESPR stock falls after Esperion’s mixed Q4 — retail remains unfazed, eyes ‘massive’ upcoming catalysts - MSN

Mar 10, 2026

H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026 - Meyka

Mar 10, 2026